Overview

FAPI-PET/CT in Psoriatic Arthritis

Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease. Therefore, this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for disease activity assessment and follow-up of psoriatic arthritis than 18F-NAF PET/CT.
Phase:
Early Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital